The Claim
In individuals with mild cognitive impairment, bilateral hippocampal subfield atrophy, particularly in CA1, subiculum, and strata radiatum/lacunosum/moleculare, is detectable at baseline in those who later progress to Alzheimer's disease and becomes more widespread at the time of conversion, indicating its role as a key early biomarker.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with mild cognitive impairment, specific regions of the hippocampus show measurable shrinkage before and at the time of progression to Alzheimer's disease, and this shrinkage is consistently observed in those who develop the disease.
See the scientific wording
In individuals with mild cognitive impairment, bilateral hippocampal subfield atrophy—particularly in CA1, subiculum, and strata radiatum/lacunosum/moleculare—is detectable at baseline in those who later progress to Alzheimer's disease, and becomes more widespread at the time of conversion, supporting its role as a key early biomarker.
Toxic tau proteins accumulate in specific inner regions of the hippocampus, causing nerve cells to lose connections and die, starting in CA1 and the subiculum, then spreading to nearby layers as the disease worsens.
What the research says
1 studyPeople with mild memory problems who later get Alzheimer's already have shrinking in specific inner parts of the hippocampus—like CA1 and subiculum—years before they get worse, and this shrinkage gets worse over time. The study found this pattern clearly and could predict who would develop Alzheimer's with very high accuracy.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.